Palmitamidohexadecanediol | 190381-46-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 鞘脂
• 英文名称: Palmitamidohexadecanediol
• 英文别名: N-[(2S,3R)-1,3-dihydroxyhexadecan-2-yl]hexadecanamide
• CAS: 190381-46-5
• 化学式: C₃₂H₆₅NO₃
• 分子量: 511.9
• InChiKey: GFUGOEQVSHGJMI-IOWSJCHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.3
• 重原子数：
  36
• 可旋转键数：
  29
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.97
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  hexadecanoyl CoA 、 Hexadecasphinganine(1+) 生成 coenzyme A 、 氢(+1)阳离子 、 Palmitamidohexadecanediol
  参考文献：
  名称：

  Myristate-derived d16:0 Sphingolipids Constitute a Cardiac Sphingolipid Pool with Distinct Synthetic Routes and Functional Properties

  摘要：

  The enzyme serine palmitoyltransferase (SPT) catalyzes the formation of the sphingoid base "backbone" from which all sphingolipids are derived. Previous studies have shown that inhibition of SPT ameliorates pathological cardiac outcomes in models of lipid overload, but the metabolites responsible for these phenotypes remain unidentified. Recent in vitro studies have shown that incorporation of the novel subunit SPTLC3 broadens the substrate specificity of SPT, allowing utilization of myristoyl-coenzyme A (CoA) in addition to its canonical substrate palmitoyl-CoA. However, the relevance of these findings in vivo has yet to be determined. The present study sought to determine whether myristate-derived d16 sphingolipids are represented among myocardial sphingolipids and, if so, whether their function and metabolic routes were distinct from those of palmitate-derived d18 sphingolipids. Data showed that d16: 0 sphingoid bases occurred in more than one-third of total dihydrosphingosine and dihydroceramides in myocardium, and a diet high in saturated fat promoted their de novo production. Intriguingly, d16-ceramides demonstrated highly limited N-acyl chain diversity, and in vitro enzyme activity assays showed that these bases were utilized preferentially to canonical bases by CerS1. Functional differences between myristate- and palmitate-derived sphingolipids were observed in that, unlike d18 sphingolipids and SPTLC2, d16 sphingolipids and SPTLC3 did not appear to contribute to myristate-induced autophagy, whereas only d16 sphingolipids promoted cell death and cleavage of poly(ADPribose) polymerase in cardiomyocytes. Thus, these results reveal a previously unappreciated component of cardiac sphingolipids with functional differences from canonical sphingolipids.

  DOI：

  10.1074/jbc.m112.428185

文献信息

• Clear aqueous ceramide composition
  申请人：Takasago International Corporation

  公开号：EP1153595A2

  公开（公告）日：2001-11-14

  Provided is a clear aqueous ceramide composition comprising 1.0 to 5.0% by weight, based on the total composition, of a ceramide represented by formula (I): wherein R1 represents a hydrocarbon group having 9 to 17 carbon atoms; and R2 represents an acyl group having 2 to 30 carbon atoms which can contain a hydroxyl group, a long-chain fatty acid having 12 to 24 carbon atoms, a nonionic surface active agent, and water. The clear aqueous composition is useful as cosmetics, bath agents, hair-careproducts, external preparations for the skin, skin protective preparations, particularly medical external preparations for the treatment or protection of the skin, or a component making up these preparations.

  本发明提供了一种透明的含水神经酰胺组合物，该组合物含有按重量计为 1.0 至 5.0%的由式(I)代表的神经酰胺： 其中 R1 代表具有 9 至 17 个碳原子的烃基；R2 代表具有 2 至 30 个碳原子的酰基，该酰基可含有羟基、 具有 12 至 24 个碳原子的长链脂肪酸、非离子表面活性剂和水。这种透明的水性组合物可用作化妆品、沐浴剂、护发产品、皮肤外用制剂、皮肤保护制剂，特别是用于治疗或保护皮肤的医用外用制剂，或这些制剂的组成部分。
• Humectant Composition
  申请人：Takasago International Corporation

  公开号：EP1946743A2

  公开（公告）日：2008-07-23

  The present invention relates to a humectant composition containing, as component (A), at least one member selected from a menthol derivative represented by the following formula (1) and p-menthane-3,8-diol: in which R is an alkylene group having 2 to 5 carbon atoms which may be substituted with at least one member selected from the group consisting of a methyl group and a hydroxyl group, and n is an integer of 1 to 3. The humectant composition of the present invention provides an excellent moisture-retention effect.

  本发明涉及一种保湿剂组合物，其中含有至少一种选自下式（1）所代表的薄荷醇衍生物和对薄荷-3,8-二醇的成分（A）： 本发明的保湿剂组合物具有优异的保湿效果。
• Lipid composition and skin care formulation containing the same
  申请人：Ishida Kenya

  公开号：US20060210522A1

  公开（公告）日：2006-09-21

  Bioavailability of a ceramide, which is a minimally soluble material of a skin care composition exhibiting an excellent effect is enhanced by combining at least one component selected from ceramides represented by Formula (1): and at least one component selected from aliphatic alcohol having 12 to 30 carbon atoms.

  将至少一种选自由式（1）表示的神经酰胺的成分与至少一种选自具有 12 至 30 个碳原子的脂肪醇的成分结合，可提高神经酰胺的生物利用率，神经酰胺是护肤组合物中具有优异功效的微溶性材料： 和至少一种选自具有 12 至 30 个碳原子的脂肪醇的成分。
• [EN] APPLICATION OF COMPOUND OR TRADITIONAL CHINESE MEDICINE EXTRACT IN PREPARATION OF NUCLEIC ACID DELIVERY AGENT AND RELATED PRODUCTS THEREOF<br/>[FR] APPLICATION D'UN COMPOSÉ OU D'UN EXTRAIT DE MÉDECINE CHINOISE TRADITIONNELLE DANS LA PRÉPARATION D'UN AGENT D'ADMINISTRATION D'ACIDE NUCLÉIQUE ET PRODUITS APPARENTÉS CORRESPONDANTS<br/>[ZH] 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
  申请人：INST BASIC MEDICAL SCIENCES CAMS

  公开号：WO2018177383A9

  公开（公告）日：2019-11-28

  [EN] The present application relates to extracting, from a traditional Chinese medicine, a plurality of compounds capable of prompting nucleic acid delivery or synthetic compounds, and promoting nucleic acid such as sRNA to absorb and enter a target cell using the extracted compounds or a plurality of combinations and promoting the nucleic acid to enter required target sites in vivo of an object.
  [FR] La présente invention concerne l'extraction, à partir d'un médicament chinois traditionnel, de plusieurs composés capables de guider l'administration d'un acide nucléique ou de composés synthétiques, et la promotion d'un acide nucléique tel qu'un sARN pour absorber et pénétrer une cellule cible à l'aide de composés extraits ou de plusieurs combinaisons ainsi que la promotion de l'acide nucléique pour pénétrer des sites cibles requis in vivo d'un sujet.
  [ZH] 本申请涉及从中药中提取多种能够促进核酸递送的化合物或合成的化合物，并利用所提取的化合物或多种组合促进核酸如sRNA吸收和进入靶细胞中，并能促进核酸进入有此需要的对象体内的靶部位。
• Keratin fiber strengthening agent and method for strengthening keratin fiber
  申请人：Takasago International Corporation

  公开号：EP0920852B1

  公开（公告）日：2005-06-01